{"classes":[{"categories":[{"measurements":[{"comment":"Despite administering HDLEN at doses of up to 350 mg/day, the maximum tolerated dose could not be determined, owing to an insufficient number of dose-limiting toxicities in the 21 patients enrolled in the trial","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The primary endpoint for the phase 1 portion of this study is to determine the maximum tolerated dose of lenalidomide that can be added to melphalan.","groups":[{"description":"All participants who received lenalidomide at\n\n25mg daily x 5 days 25mg twice daily x 5 days 25mg qAM, 50mq qPM x 5 days 50mg qAM, 75mg qPM x 5 days 75mg qAM, 100mg qPM x 5 days 100mg qAM, 150mg qPM x 5 days 150mg qAM, 200mg qPM x 5 days","id":"OG000","title":"All Phase 1 Participants"}],"paramType":"NUMBER","populationDescription":"This outcome measure only assesses Phase 1 participants","reportingStatus":"POSTED","timeFrame":"12 months","title":"Maximum Tolerated Dose (MTD) of Lenalidomide That Can be Added to Melphalan","type":"PRIMARY","unitOfMeasure":"mg/day"}